

Wright Medical Group N.V.
Supplemental Net Sales Information
(unaudited)

Three months ended July 1, 2018 net sales growth/(decline)

Product line	<u>U.S. as reported</u>	<u>Int'l constant currency</u>	<u>Int'l as reported</u>	<u>Global constant currency</u>	<u>Global as reported</u>
Lower extremities	9%	1%	6%	8%	9%
Upper extremities	22%	20%	27%	21%	23%
Biologics	5%	26%	28%	9%	10%
Sports med & other	(4%)	(41%)	(37%)	(30%)	(27%)
Total net sales	14%	10%	15%	13%	14%

Six months ended July 1, 2018 net sales growth/(decline)

Product line	<u>U.S. as reported</u>	<u>Int'l constant currency</u>	<u>Int'l as reported</u>	<u>Global constant currency</u>	<u>Global as reported</u>
Lower extremities	6%	2%	9%	5%	7%
Upper extremities	21%	19%	29%	21%	24%
Biologics	1%	12%	15%	4%	4%
Sports med & other	(1%)	(29%)	(22%)	(20%)	(15%)
Total net sales	12%	9%	17%	11%	13%

Wright Medical Group N.V.

Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share

(dollars in thousands, except per share data--unaudited)

	<u>Three months ended</u>		<u>Six months ended</u>	
	<u>July 1, 2018</u>	<u>June 25, 2017</u>	<u>July 1, 2018</u>	<u>June 25, 2017</u>
Net loss from continuing operations, as reported	\$ (90,621)	\$ (20,960)	\$ (110,528)	\$ (57,667)
Net loss from continuing operations per share, as reported	\$ (0.85)	\$ (0.20)	\$ (1.04)	\$ (0.55)
Reconciling items:				
Non-cash interest expense on convertible notes ¹	12,275	11,249	24,287	22,248
Non-cash loss on extinguishment of debt ²	39,935	—	39,935	—
Derivatives mark-to-market adjustments ²	32,879	(4,329)	34,573	(3,964)
Transaction and transition costs	1,325	3,201	2,235	6,173
Foreign currency translation expense ²	1,893	—	2,656	—
CVR mark-to-market adjustments ²	(2,523)	(3,924)	(6,447)	2,236
Contingent consideration fair value adjustment ²	365	176	779	176
U.S. tax benefit resulting from income from discontinued operations	(6,183)	—	(6,183)	—
Tax effect of reconciling items ³	1,069	(52)	859	(70)
Non-GAAP net loss from continuing operations, as adjusted	\$ (9,586)	\$ (14,639)	\$ (17,834)	\$ (30,868)
Add back amortization of intangible assets	6,009	6,999	13,150	14,396
Adjusted non-GAAP earnings	\$ (3,577)	\$ (7,640)	\$ (4,684)	\$ (16,472)
Weighted-average basic shares outstanding	106,095	104,377	106,000	104,020
Adjusted non-GAAP earnings per share	\$ (0.03)	\$ (0.07)	\$ (0.04)	\$ (0.16)

¹ Impacting interest expense, net

² Impacting other expense (income), net

³ Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations
(dollars in thousands--unaudited)

	<u>Three months ended</u>		<u>Six months ended</u>	
	<u>July 1, 2018</u>	<u>June 25, 2017</u>	<u>July 1, 2018</u>	<u>June 25, 2017</u>
Net loss from continuing operations	\$ (90,621)	\$ (20,960)	\$ (110,528)	\$ (57,667)
Interest expense, net	20,678	18,339	40,490	36,534
(Benefit) provision from income taxes	(4,462)	385	(4,257)	1,324
Depreciation	13,883	13,678	28,382	27,124
Amortization	6,009	6,999	13,150	14,396
Non-GAAP EBITDA	\$ (54,513)	\$ 18,441	\$ (32,763)	\$ 21,711
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	6,061	4,732	11,079	8,686
Other expense (income), net	72,747	(6,557)	71,747	1,418
Transaction and transition costs	1,325	3,201	2,235	6,173
Non-GAAP adjusted EBITDA	\$ 25,620	\$ 19,817	\$ 52,298	\$ 37,988
Net sales from continuing operations	205,400	179,693	403,937	356,884
Non-GAAP adjusted EBITDA margin	12.5%	11.0%	12.9%	10.6%

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations
(dollars in thousands--unaudited)

	<u>Three months ended</u>		<u>Six months ended</u>	
	<u>July 1, 2018</u>	<u>June 25, 2017</u>	<u>July 1, 2018</u>	<u>June 25, 2017</u>
Gross profit from continuing operations, as reported	\$ 159,842	\$ 141,571	\$ 317,240	\$ 281,636
Gross margins from continuing operations, as reported	77.8 %	78.8 %	78.5 %	78.9 %
Reconciling items impacting gross profit:				
Transaction and transition costs	1,326	—	2,236	685
Non-GAAP gross profit from continuing operations, as adjusted	\$ 161,168	\$ 141,571	\$ 319,476	\$ 282,321
Net sales from continuing operations	205,400	179,693	403,937	356,884
Non-GAAP adjusted gross margins from continuing operations	78.5%	78.8%	79.1%	79.1%

Wright Medical Group N.V.
Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	July 1, 2018	June 25, 2017	July 1, 2018	June 25, 2017
Net sales	\$ 205,400	\$ 179,693	\$ 403,937	\$ 356,884
Selling, general and administrative expense, as reported	\$ 140,826	\$ 130,818	\$ 278,074	\$ 260,652
Selling, general and administrative expense as a percentage of net sales, as reported	68.6 %	72.8 %	68.8 %	73.0 %
Reconciling items impacting selling, general and administrative expense:				
Transaction and transition costs - selling, general and administrative	—	3,101	—	5,388
Selling, general and administrative expense, as adjusted	\$ 140,826	\$ 127,717	\$ 278,074	\$ 255,264
Selling, general and administrative expense as a percentage of net sales, as adjusted	68.6%	71.1%	68.8%	71.5%
Research & development expense, as reported	\$ 14,665	\$ 12,547	\$ 28,564	\$ 24,979
Research & development expense as a percentage of net sales, as reported	7.1 %	7.0 %	7.1 %	7.0 %
Reconciling items impacting research & development expense:				
Transaction and transition costs - research & development	—	100	—	100
Research & development expense, as adjusted	\$ 14,665	\$ 12,447	\$ 28,564	\$ 24,879
Research & development expense as a percentage of net sales, as adjusted	7.1%	6.9%	7.1%	7.0%